Claims for Patent: 5,928,643
✉ Email this page to a colleague
Summary for Patent: 5,928,643
Title: | Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation |
Abstract: | Polypeptides and proteins comprising the CD2-binding domain of LFA-3 are disclosed. DNA sequences that code on expression for those polypeptides and proteins, methods of producing and using those polypeptides and proteins, and therapeutic and diagnostic compositions are also disclosed. Deletion mutants unable to bind CD2 and methods for their use are also disclosed. In addition, fusion proteins which comprise the CD2-binding domain of LFA-3 and a portion of a protein other than LFA-3, DNA sequences encoding those fusion proteins, methods for producing those fusion proteins, and uses of those fusion proteins are disclosed. |
Inventor(s): | Wallner; Barbara P. (Cambridge, MA), Miller; Glenn T. (Haverhill, MA), Rosa; Margaret D. (Winchester, MA) |
Assignee: | Biogen, Inc. (Cambridge, MA) |
Application Number: | 08/460,132 |
Patent Claims: | 1. A method of initiating T-cell activation comprising administering to a population of T cells a polypeptide having amino terminal amino acids 1-92 of lymphocyte functioning
associated antigen-3 (LFA-3) joined to a protein or polypeptide other than LFA-3, wherein the protein or polypeptide other than LFA-3 comprises a portion of hinge, C.sub.H 2 and C.sub.H 3 constant domains of an immunoglobulin.
2. A method of initiating T-cell activation comprising administering to a population of T cells a polypeptide having amino terminal amino acids 1-92 of lymphocyte functioning associated antigen-3 (LFA-3) [SEQ ID NO:1] and a portion of an Fc region of a human immunoglobulin IgG1 sufficient to be recognized by protein A. 3. The method of claim 2, wherein the Fc region comprises a hinge region that is capable of forming intermolecular disulfide bonds. 4. A method of initiating T-cell activation comprising administering to a population of T cells a polypeptide encoded by a DNA sequence contained in plasmid pSAB 152 ATCC Accession Number 68720. |
Details for Patent 5,928,643
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Astellas Pharma Us, Inc. | AMEVIVE | alefacept | For Injection | 125036 | January 30, 2003 | ⤷ Sign Up | 2016-07-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 5,928,643
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 9216622 | ⤷ Sign Up |
United States of America | 5914111 | ⤷ Sign Up |
United States of America | 5728677 | ⤷ Sign Up |
United States of America | 5547853 | ⤷ Sign Up |
Singapore | 47766 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.